← Back to Clinical Trials
Recruiting NCT07204561

NCT07204561 CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07204561
Status Recruiting
Phase
Sponsor Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
Condition Atopic Dermatitis (AD)
Study Type INTERVENTIONAL
Enrollment 98 participants
Start Date 2025-03-25
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
CeraVe Moisturizing CreamGalenico

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 98 participants in total. It began in 2025-03-25 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.

Eligibility Criteria

Inclusion criteria: Subjects with clinically confirmed mild-to-moderate atopic dermatitis (AD), as defined by an Eczema Area and Severity Index (EASI) score of 1-21, whose lesions will clear after treatment with a steroid and who will experience at least a 90% reduction in their EASI score. \- Participants of any gender, aged 18 years or over, from any phototype or ethnic group. Participants must be willing and able to give informed consent to participate in the study. Exclusion criteria: * Age \<18 years. Participants who are unwilling or unable to give informed consent to participate in the study. * Receiving any systemic treatment for atopic dermatitis (AD), including corticosteroids, cyclosporine, any approved biologics or JAK inhibitors. * Any dermatological disorder which, in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics (except AD).

Contact & Investigator

Central Contact

Prof.ssa Elena Campione

✉ elena.campione@ptvonline.it

📞 +39 0620908446

Frequently Asked Questions

Who can join the NCT07204561 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Atopic Dermatitis (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07204561 currently recruiting?

Yes, NCT07204561 is actively recruiting participants. Contact the research team at elena.campione@ptvonline.it for enrollment information.

Where is the NCT07204561 trial being conducted?

This trial is being conducted at Roma, Italy.

Who is sponsoring the NCT07204561 clinical trial?

NCT07204561 is sponsored by Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse. The trial plans to enroll 98 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology